This site uses cookies. To learn more, please visit our Privacy Policy. By continuing to surf on our website, you consent to our use of cookies Close [X]
Melanoma is a form of skin cancer that begins in the cells (melanocytes) that control the pigment in your skin. This illustration shows melanoma cells extending from the surface of the skin into the deeper skin layers.
MARKET DYNAMICS
Rising incidence of melanoma and other skin cancers is prominently driving the growth of malignant melanoma drugs market. In addition, the entry of biosimilars in the market is expected to increase during the review period due to the patent expiration of key branded biologics. For instance, Amgen's patent for Imlygic expires in 2021, and this is expected to offer opportunities for new players to enter the market, and, in turn, boost the market growth.
MARKET SCOPE
The "Malignant Melanoma Drugs Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of Malignant Melanoma Drugs Market with detailed market segmentation by drugs, and disease type. The Malignant Melanoma Drugs Market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Malignant Melanoma Drugs Market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The Malignant Melanoma Drugs Market is segmented on the basis of drugs, and disease type. On the basis of drugs, the market is segmented as opdivo, yervoy, mekinist+tafinlar, keytruda, cotellic, zelboraf, imlygic and generics. Based on disease type, the market is segmented as lentigo maligna melanoma, acral lentiginous melanoma, nodular melanoma, superficial spreading melanoma.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Malignant Melanoma Drugs Market based on various segments. It also provides market size and forecast estimates from year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Malignant Melanoma Drugs Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Malignant Melanoma Drugs Market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Malignant Melanoma Drugs Market in these regions.
Get more information on this report :
MARKET PLAYERS
The report covers key developments in the Malignant Melanoma Drugs Market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Malignant Melanoma Drugs Market are anticipated to have lucrative growth opportunities in the future with the rising demand for smart hospital beds in the global market. Below mentioned is the list of few companies engaged in the Malignant Melanoma Drugs Market.
The report also includes the profiles of key players in Malignant Melanoma Drugs Market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
AstraZeneca
Amgen, Inc.
F. Hoffmann-La Roche Ltd.
Bristol-Myers Squibb Company
Novartis AG
Merck and Co., Inc.
Daiichi Sankyo Company, Limited
AB Sciences.
Genentech, Inc.
ADC Therapeutics SA
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
Get more information on this report :
TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Malignant Melanoma Drugs Market - By Drugs
1.3.2 Malignant Melanoma Drugs Market - By Disease Type
1.3.3 Malignant Melanoma Drugs Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. MALIGNANT MELANOMA DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. MALIGNANT MELANOMA DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. MALIGNANT MELANOMA DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. MALIGNANT MELANOMA DRUGS - GLOBAL MARKET OVERVIEW
6.2. MALIGNANT MELANOMA DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING
7. MALIGNANT MELANOMA DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DRUGS
7.1. OVERVIEW
7.2. DRUGS MARKET FORECASTS AND ANALYSIS
7.3. OPDIVO
7.3.1. Overview
7.3.2. Opdivo Market Forecast and Analysis
7.4. YERVOY
7.4.1. Overview
7.4.2. Yervoy Market Forecast and Analysis
7.5. MEKINIST+TAFINLAR
7.5.1. Overview
7.5.2. Mekinist+Tafinlar Market Forecast and Analysis
7.6. KEYTRUDA
7.6.1. Overview
7.6.2. Keytruda Market Forecast and Analysis
7.7. COTELLIC
7.7.1. Overview
7.7.2. Cotellic Market Forecast and Analysis
7.8. ZELBORAF
7.8.1. Overview
7.8.2. Zelboraf Market Forecast and Analysis
7.9. IMLYGIC
7.9.1. Overview
7.9.2. Imlygic Market Forecast and Analysis
7.10. GENERICS
7.10.1. Overview
7.10.2. Generics Market Forecast and Analysis
8. MALIGNANT MELANOMA DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DISEASE TYPE
8.1. OVERVIEW
8.2. DISEASE TYPE MARKET FORECASTS AND ANALYSIS
8.3. LENTIGO MALIGNA MELANOMA
8.3.1. Overview
8.3.2. Lentigo Maligna Melanoma Market Forecast and Analysis
8.4. ACRAL LENTIGINOUS MELANOMA
8.4.1. Overview
8.4.2. Acral Lentiginous Melanoma Market Forecast and Analysis
8.5. NODULAR MELANOMA
8.5.1. Overview
8.5.2. Nodular Melanoma Market Forecast and Analysis
8.6. SUPERFICIAL SPREADING MELANOMA
8.6.1. Overview
8.6.2. Superficial Spreading Melanoma Market Forecast and Analysis
9. MALIGNANT MELANOMA DRUGS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Malignant Melanoma Drugs Market Overview
9.1.2 North America Malignant Melanoma Drugs Market Forecasts and Analysis
9.1.3 North America Malignant Melanoma Drugs Market Forecasts and Analysis - By Drugs
9.1.4 North America Malignant Melanoma Drugs Market Forecasts and Analysis - By Disease Type
9.1.5 North America Malignant Melanoma Drugs Market Forecasts and Analysis - By Countries
9.1.5.1 United States Malignant Melanoma Drugs Market
9.1.5.1.1 United States Malignant Melanoma Drugs Market by Drugs
9.1.5.1.2 United States Malignant Melanoma Drugs Market by Disease Type
9.1.5.2 Canada Malignant Melanoma Drugs Market
9.1.5.2.1 Canada Malignant Melanoma Drugs Market by Drugs
9.1.5.2.2 Canada Malignant Melanoma Drugs Market by Disease Type
9.1.5.3 Mexico Malignant Melanoma Drugs Market
9.1.5.3.1 Mexico Malignant Melanoma Drugs Market by Drugs
9.1.5.3.2 Mexico Malignant Melanoma Drugs Market by Disease Type
9.2. EUROPE
9.2.1 Europe Malignant Melanoma Drugs Market Overview
9.2.2 Europe Malignant Melanoma Drugs Market Forecasts and Analysis
9.2.3 Europe Malignant Melanoma Drugs Market Forecasts and Analysis - By Drugs
9.2.4 Europe Malignant Melanoma Drugs Market Forecasts and Analysis - By Disease Type
9.2.5 Europe Malignant Melanoma Drugs Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Malignant Melanoma Drugs Market
9.2.5.1.1 Germany Malignant Melanoma Drugs Market by Drugs
9.2.5.1.2 Germany Malignant Melanoma Drugs Market by Disease Type
9.2.5.2 France Malignant Melanoma Drugs Market
9.2.5.2.1 France Malignant Melanoma Drugs Market by Drugs
9.2.5.2.2 France Malignant Melanoma Drugs Market by Disease Type
9.2.5.3 Italy Malignant Melanoma Drugs Market
9.2.5.3.1 Italy Malignant Melanoma Drugs Market by Drugs
9.2.5.3.2 Italy Malignant Melanoma Drugs Market by Disease Type
9.2.5.4 Spain Malignant Melanoma Drugs Market
9.2.5.4.1 Spain Malignant Melanoma Drugs Market by Drugs
9.2.5.4.2 Spain Malignant Melanoma Drugs Market by Disease Type
9.2.5.5 United Kingdom Malignant Melanoma Drugs Market
9.2.5.5.1 United Kingdom Malignant Melanoma Drugs Market by Drugs
9.2.5.5.2 United Kingdom Malignant Melanoma Drugs Market by Disease Type
9.2.5.6 Rest of Europe Malignant Melanoma Drugs Market
9.2.5.6.1 Rest of Europe Malignant Melanoma Drugs Market by Drugs
9.2.5.6.2 Rest of Europe Malignant Melanoma Drugs Market by Disease Type
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Malignant Melanoma Drugs Market Overview
9.3.2 Asia-Pacific Malignant Melanoma Drugs Market Forecasts and Analysis
9.3.3 Asia-Pacific Malignant Melanoma Drugs Market Forecasts and Analysis - By Drugs
9.3.4 Asia-Pacific Malignant Melanoma Drugs Market Forecasts and Analysis - By Disease Type
9.3.5 Asia-Pacific Malignant Melanoma Drugs Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Malignant Melanoma Drugs Market
9.3.5.1.1 Australia Malignant Melanoma Drugs Market by Drugs
9.3.5.1.2 Australia Malignant Melanoma Drugs Market by Disease Type
9.3.5.2 China Malignant Melanoma Drugs Market
9.3.5.2.1 China Malignant Melanoma Drugs Market by Drugs
9.3.5.2.2 China Malignant Melanoma Drugs Market by Disease Type
9.3.5.3 India Malignant Melanoma Drugs Market
9.3.5.3.1 India Malignant Melanoma Drugs Market by Drugs
9.3.5.3.2 India Malignant Melanoma Drugs Market by Disease Type
9.3.5.4 Japan Malignant Melanoma Drugs Market
9.3.5.4.1 Japan Malignant Melanoma Drugs Market by Drugs
9.3.5.4.2 Japan Malignant Melanoma Drugs Market by Disease Type
9.3.5.5 South Korea Malignant Melanoma Drugs Market
9.3.5.5.1 South Korea Malignant Melanoma Drugs Market by Drugs
9.3.5.5.2 South Korea Malignant Melanoma Drugs Market by Disease Type
9.3.5.6 Rest of Asia-Pacific Malignant Melanoma Drugs Market
9.3.5.6.1 Rest of Asia-Pacific Malignant Melanoma Drugs Market by Drugs
9.3.5.6.2 Rest of Asia-Pacific Malignant Melanoma Drugs Market by Disease Type
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Malignant Melanoma Drugs Market Overview
9.4.2 Middle East and Africa Malignant Melanoma Drugs Market Forecasts and Analysis
9.4.3 Middle East and Africa Malignant Melanoma Drugs Market Forecasts and Analysis - By Drugs
9.4.4 Middle East and Africa Malignant Melanoma Drugs Market Forecasts and Analysis - By Disease Type
9.4.5 Middle East and Africa Malignant Melanoma Drugs Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Malignant Melanoma Drugs Market
9.4.5.1.1 South Africa Malignant Melanoma Drugs Market by Drugs
9.4.5.1.2 South Africa Malignant Melanoma Drugs Market by Disease Type
9.4.5.2 Saudi Arabia Malignant Melanoma Drugs Market
9.4.5.2.1 Saudi Arabia Malignant Melanoma Drugs Market by Drugs
9.4.5.2.2 Saudi Arabia Malignant Melanoma Drugs Market by Disease Type
9.4.5.3 U.A.E Malignant Melanoma Drugs Market
9.4.5.3.1 U.A.E Malignant Melanoma Drugs Market by Drugs
9.4.5.3.2 U.A.E Malignant Melanoma Drugs Market by Disease Type
9.4.5.4 Rest of Middle East and Africa Malignant Melanoma Drugs Market
9.4.5.4.1 Rest of Middle East and Africa Malignant Melanoma Drugs Market by Drugs
9.4.5.4.2 Rest of Middle East and Africa Malignant Melanoma Drugs Market by Disease Type
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Malignant Melanoma Drugs Market Overview
9.5.2 South and Central America Malignant Melanoma Drugs Market Forecasts and Analysis
9.5.3 South and Central America Malignant Melanoma Drugs Market Forecasts and Analysis - By Drugs
9.5.4 South and Central America Malignant Melanoma Drugs Market Forecasts and Analysis - By Disease Type
9.5.5 South and Central America Malignant Melanoma Drugs Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Malignant Melanoma Drugs Market
9.5.5.1.1 Brazil Malignant Melanoma Drugs Market by Drugs
9.5.5.1.2 Brazil Malignant Melanoma Drugs Market by Disease Type
9.5.5.2 Argentina Malignant Melanoma Drugs Market
9.5.5.2.1 Argentina Malignant Melanoma Drugs Market by Drugs
9.5.5.2.2 Argentina Malignant Melanoma Drugs Market by Disease Type
9.5.5.3 Rest of South and Central America Malignant Melanoma Drugs Market
9.5.5.3.1 Rest of South and Central America Malignant Melanoma Drugs Market by Drugs
9.5.5.3.2 Rest of South and Central America Malignant Melanoma Drugs Market by Disease Type
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL MALIGNANT MELANOMA DRUGS MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Middle East and Africa
10.5 South and Central America
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. MALIGNANT MELANOMA DRUGS MARKET, KEY COMPANY PROFILES
12.1. ASTRAZENECA
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. AMGEN, INC.
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. F. HOFFMANN-LA ROCHE LTD.
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. BRISTOL-MYERS SQUIBB COMPANY
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. NOVARTIS AG
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. MERCK AND CO., INC.
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. DAIICHI SANKYO COMPANY, LIMITED
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. AB SCIENCES.
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. GENENTECH, INC.
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. ADC THERAPEUTICS SA
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies
1. AstraZeneca
2. Amgen, Inc.
3. F. Hoffmann-La Roche Ltd.
4. Bristol-Myers Squibb Company
5. Novartis AG
6. Merck and Co., Inc.
7. Daiichi Sankyo Company, Limited
8. AB Sciences.
9. Genentech, Inc.
10. ADC Therapeutics SA
